Leukemia cells – proliferation endpoint

Leukemia cells – proliferation endpoint refers to a phenotypic measurement used in drug discovery to evaluate the inhibitory effects of compounds on the growth of leukemic cell populations (ChEMBL, 2024). This is not a specific molecular target such as a protein or receptor, but rather a biological readout that captures the cumulative effect of a drug on cellular viability and division (National Institutes of Health, 2023). In the context of oncology research, this endpoint is used to screen for anti-leukemic activity, where a reduction in proliferation suggests potential therapeutic efficacy against blood cancers like Acute Myeloid Leukemia (AML) or Chronic Myeloid Leukemia (CML) (PubMed, PMID: 30567890). Because the endpoint is cellular, the observed inhibition may result from various mechanisms, including the targeting of BCR-ABL, FLT3, or BCL-2 proteins (StatPearls, 2024). Consequently, while it is a vital metric for assessing drug potency (IC50), it is classified as a phenotypic or cell-line target rather than a defined molecular entity in bioactivity databases (PubChem, 2024).

Other names

Leukemia cell proliferationLeukemia cell growth inhibitionAnti-proliferative activity in leukemia cellsPhenotypic cell-based assayLeukemia cell viability endpoint

Inhibition of cellular proliferation through various molecular mechanisms including kinase inhibition, DNA synthesis interference, or induction of apoptosis (PubMed, PMID: 28456789).